1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Emergency telephone number:
ChemSafe (24 hours): +44 (0)208 762 8322

Contact E-Mail: pfizer-MSDS@pfizer.com

Material Name: Viracept® (Nelfinavir Mesylate) Oral Powder, 50 mg/g

<table>
<thead>
<tr>
<th>Trade Name:</th>
<th>Viracept</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Family:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Intended Use:</td>
<td>Pharmaceutical product used as HIV protease inhibitor</td>
</tr>
</tbody>
</table>

2. HAZARDS IDENTIFICATION

Appearance: White to off-white powder

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

**Short Term:** Dust may cause irritation. Active ingredient is not a skin irritant. Not acutely toxic (based on animal data).

**Known Clinical Effects:** Diarrhea is the most common side effect seen during clinical use.

**EU Indication of danger:** Not classified

**Australian Hazard Classification (NOHSC):** Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nelfinavir Mesylate</td>
<td>159989-65-8</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>5.85</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dibasic Potassium Phosphate</td>
<td>7758-11-4</td>
<td>231-834-5</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sucrose Palmitate</td>
<td>26446-38-8</td>
<td>247-706-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>
MATERIAL SAFETY DATA SHEET

Material Name: Viracept® (Nelfinavir Mesylate) Oral Powder, 50 mg/g
Revision date: 22-Sep-2009

Page 2 of 7
Version: 1.4

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>UN Number</th>
<th>Hazard Rating</th>
<th>Proprietary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prosweet Powder</td>
<td>NOT ASSIGNED</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Maltodextrin</td>
<td>9050-36-6</td>
<td>232-940-4</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Aspartame</td>
<td>22839-47-0</td>
<td>245-261-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Crospovidone</td>
<td>9003-39-8</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Hypromellose</td>
<td>9004-65-3</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Purified water</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits fumes of carbon monoxide, nitrogen oxides, and sulphur dioxide.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. Avoid breathing dust, vapor or mist. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Nelfinavir Mesylate
Pfizer OEL TWA-8 Hr: 3000µg/m³

Microcrystalline cellulose
ACGIH Threshold Limit Value (TWA) 10 mg/m³ TWA
Australia TWA 10 mg/m³
Belgium OEL - TWA Listed
Estonia OEL - TWA Listed
France OEL - TWA Listed
Ireland OEL - TWAs Listed
Latvia OEL - TWA Listed
OSHA - Final PELS - TWAs: 15 mg/m³ total
Portugal OEL - TWA Listed
Romania OEL - TWA Listed
Spain OEL - TWA Listed


Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.
9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Powder</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Color:</td>
<td>White to off-white</td>
</tr>
<tr>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

| Stability: | Stable under normal conditions of use. |
| Conditions to Avoid: | Fine particles (such as dust and mists) may fuel fires/explosions. |
| Incompatible Materials: | None known |

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

- Microcrystalline cellulose
  - Rat Oral LD50 > 5000 mg/kg
  - Rabbit Dermal LD50 > 2000 mg/kg

- Nelfinavir Mesylate
  - Rat Oral LD50 > 1000 mg/kg
  - Mouse Oral LD50 > 1000 mg/kg
  - Rat Dermal LD50 > 2000 mg/kg

- Hypromellose
  - Rat Oral LD50 > 10,000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

- Microcrystalline cellulose
  - Skin Irritation Rabbit Non-irritating
  - Eye Irritation Rabbit Non-irritating

- Nelfinavir Mesylate
  - Skin Sensitization - Beuhler Guinea Pig Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

- Nelfinavir Mesylate
  - 26 Week(s) Rat Oral 1000 mg/kg/day LOAEL Liver
  - 26 Week(s) Monkey Oral 250 mg/kg/day LOAEL Gastrointestinal system

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))
11. TOXICOLOGICAL INFORMATION

Nelfinavir Mesylate
Reproductive & Fertility  Rat  Oral 1000 mg/kg/day  NOAEL  No effects at maximum dose
Embryo / Fetal Development  Rat  Oral 1000 mg/kg/day  NOAEL  Not Teratogenic
Embryo / Fetal Development  Rabbit  Oral 1000 mg/kg/day  NOAEL  Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Nelfinavir Mesylate
In Vitro Bacterial Mutagenicity (Ames)  Salmonella, E. coli  Negative
In Vitro Chromosome Aberration  Human Lymphocytes  Negative
In Vivo Micronucleus  Mouse Bone Marrow  Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Nelfinavir Mesylate
2 Year(s)  Rat  Oral 300 mg/kg/day  LOAEL  Thyroid, neoplasms
2 Year(s)  Mouse  Oral 1000 mg/kg/day  NOAEL  Not carcinogenic

Carcinogen Status:  None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Crospovidone
IARC:  Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview:  The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures:  Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger:  Not classified
15. REGULATORY INFORMATION

OSHA Label:
Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:
None required
This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Nelfinavir Mesylate
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4

Dibasic Potassium Phosphate
Inventory - United States TSCA - Sect. 8(b) Listed
Australia (AICS): Listed
EU EINECS/ELINCS List 231-834-5

Sucrose Palmitate
Inventory - United States TSCA - Sect. 8(b) Listed
Australia (AICS): Listed
EU EINECS/ELINCS List 247-706-7

Maltodextrin
Inventory - United States TSCA - Sect. 8(b) Listed
Australia (AICS): Listed
REACH - Annex IV - Exemptions from the obligations of Register: Present
EU EINECS/ELINCS List 232-940-4

Aspartame
Inventory - United States TSCA - Sect. 8(b) Listed
Australia (AICS): Listed
EU EINECS/ELINCS List 245-261-3

Crospovidone
Inventory - United States TSCA - Sect. 8(b) Listed
Australia (AICS): Listed

Hypermellose
Inventory - United States TSCA - Sect. 8(b) Listed
Australia (AICS): Listed
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4

Microcrystalline cellulose
Inventory - United States TSCA - Sect. 8(b) Listed
Australia (AICS): Listed
15. REGULATORY INFORMATION

| EU EINECS/ELINCS List | 232-674-9 |

Purified water
- Inventory - United States TSCA - Sect. 8(b): Listed
- Australia (AICS): Listed
- REACH - Annex IV - Exemptions from the obligations of Register: Present
- EU EINECS/ELINCS List: 231-791-2

16. OTHER INFORMATION

Data Sources: Pfizer proprietary drug development information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 5 - Fire Fighting Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet